| Identification | Back Directory | [Name]
1169630-40-3 | [CAS]
1169630-40-3 | [Synonyms]
Ste-Glu-AEEA-AEEA-OSU
Octa(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA)-OR
17-((S)-1-CARBOXY-3-{2-[2-({2-[2-(2,5-DIOXO-PYRROLIDIN-1-YLOXYCARBONYL METHOXY)ETHOXY]ETHYLCARBAMOYL}METHOXY)ETHOXY]ETHYLCARBAMOYL}PROPYLCARBAMOYL)-HEPTADECANOIC ACID
18-[[(1S)-1-carboxy-4-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]-18-oxo-octadecanoic acid | [Molecular Formula]
C39H66N4O15 | [MDL Number]
MFCD32704903 | [MOL File]
1169630-40-3.mol | [Molecular Weight]
830.96 |
| Chemical Properties | Back Directory | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Storage temp. 2-8°C | [form ]
white to off-white powder | [pka]
3.52±0.10(Predicted) | [Appearance]
White to off-white Solid | [InChIKey]
DVGUZQKRMQLDDD-HKBQPEDESA-N | [SMILES]
C(C(O)=O)CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(ON1C(=O)CCC1=O)=O |
| Hazard Information | Back Directory | [Description]
Ste-Glu-AEEA-AEEA-OSU (CAS 1169630-40-3, 95%~99% purity) is a key fatty acid side-chain intermediate used in the synthesis of the GLP-1R agonist semaglutide. Attaching this intermediate to the peptide backbone of the peptide drug semaglutide can significantly prolong the drug’s half-life and improve patient compliance. | [Uses]
Ste-Glu-AEEA-AEEA-OSU is an intermediate of semaglutide, a glucagon-like peptide-1 (GLP-1) analog with significant hypoglycemic efficacy.
| [Biological Functions]
Both Ste-Glu-AEEA-AEEA-OSU and Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH (1662688-20-1) are key side chains in the synthesis of the peptide drug semaglutide, but they serve different functions. Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH is an integrated side-chain intermediate; whereas Ste-Glu-AEEA-AEEA-OSU is a modified fragment in which the terminal carboxyl group has already been activated to form an N-hydroxysuccinimide ester (NHS/OSU active ester). Researchers can use it either to directly modify pre-synthesised main-chain peptides in solution, or to carry out bulk modification on the resin during the final stage of solid-phase synthesis (SPPS). |
|
|